Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.42 |
| ▸ | LPL | P06858 | 6/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21973818 | 1.00 | CA1 (0.45) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL4515280 | 0.87 | CA1 (0.51) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL1574216 | 0.87 | CA1 (0.51) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL12224514 | 0.87 | LIPG (0.47) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL20305691 | 0.87 | HIF1A (0.47) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL12224516 | 0.87 | LIPG (0.47) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL21932236 | 0.84 | CA1 (0.50) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL24573014 | 0.83 | APP (0.46) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL18428794 | 0.83 | APP (0.46) | CA1CA2CA9AAK1HIF1A | |
| SCHEMBL15786149 | 0.83 | APP (0.46) | CA1CA2CA9AAK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-31 | — | — | US | disclosed |
| US-9547008-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9547008-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160025735-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-20160025735-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | CA1 541/4885CA2 1248/4885CA9 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.